PSO Manager's User Manual Home

CLINICAL EFFECTS: Increase hypoprothrombinemic effects of warfarin. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should be monitored for changes in . prothrombin time when a HMG Co-A reductase inhibitor is added to or . discontinued from warfarin therapy, or if the dosage of the HMG Co-A . reductase inhibitor is adjusted. ................
................